CKPT vs. LPTX, INZY, ACIU, KMDA, MGNX, XOMA, NKTX, ALXO, AVIR, and AMRN
Should you be buying Checkpoint Therapeutics stock or one of its competitors? The main competitors of Checkpoint Therapeutics include Leap Therapeutics (LPTX), Inozyme Pharma (INZY), AC Immune (ACIU), Kamada (KMDA), MacroGenics (MGNX), XOMA (XOMA), Nkarta (NKTX), ALX Oncology (ALXO), Atea Pharmaceuticals (AVIR), and Amarin (AMRN). These companies are all part of the "pharmaceutical preparations" industry.
Leap Therapeutics (NASDAQ:LPTX) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.
Checkpoint Therapeutics has lower revenue, but higher earnings than Leap Therapeutics. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.
Leap Therapeutics received 118 more outperform votes than Checkpoint Therapeutics when rated by MarketBeat users. Likewise, 68.79% of users gave Leap Therapeutics an outperform vote while only 66.54% of users gave Checkpoint Therapeutics an outperform vote.
In the previous week, Checkpoint Therapeutics had 3 more articles in the media than Leap Therapeutics. MarketBeat recorded 4 mentions for Checkpoint Therapeutics and 1 mentions for Leap Therapeutics. Checkpoint Therapeutics' average media sentiment score of 1.87 beat Leap Therapeutics' score of 0.44 indicating that Leap Therapeutics is being referred to more favorably in the media.
30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 22.0% of Checkpoint Therapeutics shares are owned by institutional investors. 11.3% of Leap Therapeutics shares are owned by insiders. Comparatively, 2.1% of Checkpoint Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Leap Therapeutics has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.
Leap Therapeutics has a net margin of 0.00% compared to Leap Therapeutics' net margin of -50,336.89%. Leap Therapeutics' return on equity of 0.00% beat Checkpoint Therapeutics' return on equity.
Leap Therapeutics presently has a consensus price target of $10.40, indicating a potential upside of 372.73%. Checkpoint Therapeutics has a consensus price target of $22.60, indicating a potential upside of 779.38%. Given Leap Therapeutics' higher probable upside, analysts clearly believe Checkpoint Therapeutics is more favorable than Leap Therapeutics.
Summary
Leap Therapeutics beats Checkpoint Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Checkpoint Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CKPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Checkpoint Therapeutics Competitors List
Related Companies and Tools
